CAD18.76
0.48% day before yesterday
Toronto, Aug 08, 04:59 pm CET
ISIN
CA0717051076
Symbol
BLCO

Bausch + Lomb Stock price

CAD18.76
-0.42 2.19% 1M
-4.41 19.03% 6M
-7.20 27.74% YTD
-3.10 14.18% 1Y
-1.03 5.20% 3Y
-6.74 26.43% 5Y
-6.74 26.43% 10Y
-6.74 26.43% 20Y
Toronto, Closing price Fri, Aug 08 2025
-0.09 0.48%
ISIN
CA0717051076
Symbol
BLCO

Key metrics

Basic
Market capitalization
CAD6.6b
Enterprise Value
CAD13.1b
Net debt
CAD6.5b
Cash
CAD365.8m
Shares outstanding
353.8m
Valuation (TTM | estimate)
P/E
negative | 27.7
P/S
1.0 | 0.9
EV/Sales
2.0 | 1.9
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
48.1%
Return on Equity
-4.9%
ROCE
0.8%
ROIC
0.5%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
CAD6.7b | CAD7.1b
EBITDA
CAD514.4m | CAD1.2b
EBIT
CAD137.5m | CAD810.1m
Net Income
CAD-375.5m | CAD239.8m
Free Cash Flow
CAD-226.9m
Growth (TTM | estimate)
Revenue
8.8% | 7.1%
EBITDA
-20.8% | 77.8%
EBIT
-49.2% | 186.0%
Net Income
40.1% | 155.0%
Free Cash Flow
-20.4%
Margin (TTM | estimate)
Gross
59.7%
EBITDA
7.7% | 17.1%
EBIT
2.0%
Net
-5.6% | 3.4%
Free Cash Flow
-3.4%
More
EPS
CAD-1.1
FCF per Share
CAD-0.6
Short interest
0.1%
Employees
13k
Rev per Employee
CAD500.0k
Show more

Is Bausch + Lomb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Bausch + Lomb Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Bausch + Lomb forecast:

10x Buy
53%
8x Hold
42%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a Bausch + Lomb forecast:

Buy
53%
Hold
42%
Sell
5%

Financial data from Bausch + Lomb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,727 6,727
9% 9%
100%
- Direct Costs 2,712 2,712
12% 12%
40%
4,015 4,015
7% 7%
60%
- Selling and Administrative Expenses 3,005 3,005
13% 13%
45%
- Research and Development Expense 494 494
9% 9%
7%
514 514
21% 21%
8%
- Depreciation and Amortization 377 377
0% 0%
6%
EBIT (Operating Income) EBIT 138 138
49% 49%
2%
Net Profit -375 -375
40% 40%
-6%

In millions CAD.

Don't miss a Thing! We will send you all news about Bausch + Lomb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Head office Canada
CEO Brenton Saunders
Employees 13,300
Founded 1853
Website ir.bausch.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today